| Year |
Citation |
Score |
| 2022 |
Hertler C, Seystahl K, Le Rhun E, Wirsching HG, Roth P, Weller M, Gramatzki D. Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. PMID 35906902 DOI: 10.1093/neuonc/noac172 |
0.371 |
|
| 2021 |
Chen J, Sun S, Ren L, Hua L, Wang D, Xie Q, Wirsching HG, Deng J, Weller M, Gong Y. mA Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes. Frontiers in Oncology. 11: 760892. PMID 35004283 DOI: 10.3389/fonc.2021.760892 |
0.43 |
|
| 2021 |
Maas SLN, Stichel D, Hielscher T, Sievers P, Berghoff AS, Schrimpf D, Sill M, Euskirchen P, Blume C, Patel A, Dogan H, Reuss D, Dohmen H, Stein M, Reinhardt A, ... ... Wirsching HG, et al. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100784. PMID 34618539 DOI: 10.1200/JCO.21.00784 |
0.461 |
|
| 2021 |
Wirsching HG, Weller M, Balabanov S, Roth P. Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. Cancers. 13. PMID 34203062 DOI: 10.3390/cancers13123073 |
0.398 |
|
| 2021 |
Wirsching HG, Steiner L, Becker D, Regli L, Andratschke N, Kulcsar Z, Roth P, Weller M. Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. Neuro-Oncology. PMID 34145883 DOI: 10.1093/neuonc/noab119 |
0.392 |
|
| 2021 |
Mastall M, Wolpert F, Gramatzki D, Imbach L, Becker D, Schmick A, Hertler C, Roth P, Weller M, Wirsching HG. Survival of brain tumour patients with epilepsy. Brain : a Journal of Neurology. PMID 33974079 DOI: 10.1093/brain/awab188 |
0.432 |
|
| 2021 |
Vils A, Bogowicz M, Tanadini-Lang S, Vuong D, Saltybaeva N, Kraft J, Wirsching HG, Gramatzki D, Wick W, Rushing E, Reifenberger G, Guckenberger M, Weller M, Andratschke N. Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Frontiers in Oncology. 11: 636672. PMID 33937035 DOI: 10.3389/fonc.2021.636672 |
0.418 |
|
| 2021 |
Wirsching HG, Silginer M, Ventura E, Macnair W, Burghardt I, Claassen M, Gatti S, Wichmann J, Riemer C, Schneider H, Weller M. Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. Molecular Therapy Oncolytics. 20: 166-174. PMID 33575479 DOI: 10.1016/j.omto.2020.12.009 |
0.4 |
|
| 2021 |
Wirsching HG, Roth P, Weller M. A vasculature-centric approach to developing novel treatment options for glioblastoma. Expert Opinion On Therapeutic Targets. PMID 33482697 DOI: 10.1080/14728222.2021.1881062 |
0.39 |
|
| 2020 |
Wirsching HG, Roelcke U, Weller J, Hundsberger T, Hottinger AF, von Moos R, Caparrotti F, Conen K, Remonda L, Roth P, Ochsenbein AF, Tabatabai G, Weller M. MRI and 18FET-PET predict survival benefit from bevacizumab plus radiotherapy in patients with IDH wild-type glioblastoma: results from the randomized ARTE trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32967939 DOI: 10.1158/1078-0432.CCR-20-2096 |
0.361 |
|
| 2020 |
Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS, Neidert MC, Wirsching HG, Mawrin C, Ketter R, Paulus W, Reifenberger G, Lamszus K, Westphal M, Etminan N, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica. PMID 32642869 DOI: 10.1007/S00401-020-02188-W |
0.338 |
|
| 2020 |
Wirsching HG, Morel C, Roth P, Weller M. Socioeconomic burden and quality of life in meningioma patients. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. PMID 32128657 DOI: 10.1007/s11136-020-02461-1 |
0.339 |
|
| 2020 |
Wirsching HG, Weller M. Does Neuronal Activity Promote Glioma Progression? Trends in Cancer. 6: 1-3. PMID 31952775 DOI: 10.1016/j.trecan.2019.11.002 |
0.323 |
|
| 2019 |
Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, et al. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. Jci Insight. 4. PMID 31292299 DOI: 10.1172/Jci.Insight.128217 |
0.423 |
|
| 2019 |
Paramasivam N, Hübschmann D, Toprak UH, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers AK, Jones DTW, Gu Z, Werner J, Uhrig S, ... Wirsching HG, et al. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathologica. PMID 31069492 DOI: 10.1007/s00401-019-02008-w |
0.374 |
|
| 2019 |
Wirsching HG, Weller M. [Update on primary brain tumours]. Therapeutische Umschau. Revue Therapeutique. 75: 438-443. PMID 30935361 DOI: 10.1024/0040-5930/a001021 |
0.444 |
|
| 2018 |
Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winther-Kristensen B, Brokinkel B, Ketter R, et al. Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica. PMID 30382370 DOI: 10.1007/S00401-018-1924-X |
0.336 |
|
| 2018 |
Wirsching HG, Richter JK, Sahm F, Morel C, Krayenbuehl N, Rushing EJ, von Deimling A, Valavanis A, Weller M. Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. Journal of Neuro-Oncology. PMID 30196368 DOI: 10.1007/S11060-018-2996-0 |
0.432 |
|
| 2018 |
Cimino PJ, McFerrin L, Wirsching HG, Arora S, Bolouri H, Rabadan R, Weller M, Holland EC. Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro-Oncology. PMID 29982740 DOI: 10.1093/Neuonc/Noy108 |
0.412 |
|
| 2018 |
Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica. PMID 29627952 DOI: 10.1007/S00401-018-1844-9 |
0.407 |
|
| 2017 |
Schneider H, Lohmann B, Wirsching HG, Hasenbach K, Rushing EJ, Frei K, Pruschy M, Tabatabai G, Weller M. Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. Oncotarget. 8: 87124-87135. PMID 29152068 DOI: 10.18632/Oncotarget.19894 |
0.387 |
|
| 2017 |
Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathologica Communications. 5: 39. PMID 28532485 DOI: 10.1186/S40478-017-0443-7 |
0.44 |
|
| 2017 |
Sahm F, Schrimpf D, Stichel D, Jones DT, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. The Lancet. Oncology. PMID 28314689 DOI: 10.1016/S1470-2045(17)30155-9 |
0.417 |
|
| 2016 |
Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nature Reviews. Clinical Oncology. PMID 28031556 DOI: 10.1038/nrclinonc.2016.204 |
0.429 |
|
| 2016 |
Wirsching HG, Weller M. The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Current Treatment Options in Oncology. 17: 51. PMID 27501915 DOI: 10.1007/s11864-016-0430-4 |
0.453 |
|
| 2016 |
Wirsching HG, Galanis E, Weller M. Glioblastoma. Handbook of Clinical Neurology. 134: 381-97. PMID 26948367 DOI: 10.1016/B978-0-12-802997-8.00023-2 |
0.431 |
|
| 2016 |
Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology. PMID 26823503 DOI: 10.1227/01.Neu.0000467098.06935.3D |
0.459 |
|
| 2016 |
Wirsching HG, Morel C, Gmür C, Neidert MC, Baumann CR, Valavanis A, Rushing EJ, Krayenbühl N, Weller M. Predicting outcome of epilepsy after meningioma resection. Neuro-Oncology. 18: 1002-10. PMID 26683139 DOI: 10.1093/Neuonc/Nov303 |
0.382 |
|
| 2015 |
Wirsching HG, Happold C, Roth P, Weller M. Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology. 27: 502-9. PMID 26397765 DOI: 10.1097/CCO.0000000000000236 |
0.377 |
|
| 2015 |
Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, et al. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2057-64. PMID 25655102 DOI: 10.1158/1078-0432.Ccr-14-2737 |
0.381 |
|
| 2014 |
Wirsching HG, Tritschler I, Palla A, Renner C, Weller M, Tabatabai G. The management of lomustine overdose in malignant glioma patients. Neuro-Oncology Practice. 1: 178-183. PMID 26034630 DOI: 10.1093/nop/npu023 |
0.42 |
|
| 2014 |
Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, Tabatabai G. Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain : a Journal of Neurology. 137: 433-48. PMID 24355709 DOI: 10.1093/brain/awt333 |
0.321 |
|
| Show low-probability matches. |